021-51111890
购物车（）
sales@molnova.cn
CCT 137690
CAS No. 1095382-05-0
CCT 137690 ( CCT-137690 | CCT137690 )
产品货号. M10372 CAS No. 1095382-05-0
一种有效的、口服生物可利用的 Aurora 激酶抑制剂，对于 Aurora A/B/C 的 IC50 为 15/25/19 nM；在一系列人类肿瘤细胞系中表现出抗增殖活性，包括 SW620 结肠癌 (GI50=0.30 uM) 和 A2780 卵巢癌细胞系 (GI50=0.14 uM)；在 SW620 结肠癌异种移植物中表现出体内功效，未观察到毒性。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ￥413 | 有现货 |
|
| 5MG | ￥583 | 有现货 |
|
| 10MG | ￥753 | 有现货 |
|
| 25MG | ￥1466 | 有现货 |
|
| 50MG | ￥2657 | 有现货 |
|
| 100MG | ￥4131 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称CCT 137690
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述一种有效的、口服生物可利用的 Aurora 激酶抑制剂，对于 Aurora A/B/C 的 IC50 为 15/25/19 nM；在一系列人类肿瘤细胞系中表现出抗增殖活性，包括 SW620 结肠癌 (GI50=0.30 uM) 和 A2780 卵巢癌细胞系 (GI50=0.14 uM)；在 SW620 结肠癌异种移植物中表现出体内功效，未观察到毒性。
-
产品描述A potent, orally bioavailable Aurora kinases inhibitor with IC50 of 15/25/19 nM for Aurora A/B/C; displays antiproliferative activity in a range of human tumor cell lines, including SW620 colon carcinoma (GI50=0.30 uM) and A2780 ovarian cancer cell line (GI50=0.14 uM); exhibits in vivo efficacy with no observed toxicities in SW620 colon carcinoma xenografts.
-
体外实验CCT 137690 displays antiproliferative activity in a range of human tumor cell lines, including SW620 colon carcinoma (GI50=0.30 μM) and A2780 ovarian cancer cell line (GI50=0.14 μM). CCT 137690 inhibits in vitro phosphorylation of histone H3. CCT 137690 is a moderate inhibitor of the hERG ion-channel (IC50=3.0 μM). CCT137690 efficiently inhibits histone H3 and TACC3 phosphorylation (Aurora B and Aurora A substrates, respectively) in HCT116 and HeLa cells. Continuous exposure of tumour cells to the inhibitor causes multipolar spindle formation, chromosome misalignment, polyploidy and apoptosis.
-
体内实验CCT 137690 slows the growth of the SW620 xenografts with no observed toxicity. CCT 137690 significantly inhibits tumour growth in a transgenic mouse model of neuroblastoma (TH-MYCN) that overexpresses MYCN protein and is predisposed to spontaneous neuroblastoma formation.
-
同义词CCT-137690 | CCT137690
-
通路Cell Cycle/DNA Damage
-
靶点Aurora Kinase
-
受体AuroraA|AuroraB|AuroraC
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number1095382-05-0
-
分子量551.4813
-
分子式C26H31BrN8O
-
纯度>98% (HPLC)
-
溶解度10 mM in DMSO
-
SMILESCN1CCN(C2=CC=C(C3=NC4=C(N5CCN(CC6=NOC(C)=C6)CC5)C(Br)=CN=C4N3)C=C2)CC1
-
化学全称3H-Imidazo[4,5-b]pyridine, 6-bromo-7-[4-[(5-methyl-3-isoxazolyl)methyl]-1-piperazinyl]-2-[4-(4-methyl-1-piperazinyl)phenyl]-
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Bavetsias V, et al. J Med Chem. 2010 Jul 22;53(14):5213-28.
2. Faisal A, et al. Mol Cancer Ther. 2011 Nov;10(11):2115-23.
3. Moore AS, et al. Leukemia. 2012 Jul;26(7):1462-70.
